Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
DSGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.60 - $7.77
Previous CloseN/A
Volume97.34K
Average Volume (3M)111.75K
Market Cap
$293.85M
Enterprise Value-$22.71M
Total Cash (Recent Filing)$216.28M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 05, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding56,948,128
10 Day Avg. Volume161,667
30 Day Avg. Volume111,750
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-38.63
Enterprise Value/Gross Profit133.61
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$5.00Price Target Upside-6.19% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe new candidate DT-216P2 has demonstrated favorable safety and improved PK in initial data from the ongoing Phase 1 SAD study.
Financial PositionDSGN reported $229.7M in cash and equivalents, expected to fund operating expenses into 2029.
Bears Say
Clinical DelaysThe US clinical hold could add to the delays seen in the program.
Regulatory ChallengesA clinical hold notice was received from the FDA in response to the IND submission, citing nonclinical deficiencies.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $2.60 and its highest was $7.77 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $293.85M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 81 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.01.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Overvalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 56,948,128 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 7.809%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
Design Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (-6.19% Downside)
$5.00 (-6.19% Downside)
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.27%
12-Months-Change
Fundamentals
Return on Equity
-26.77%
Trailing 12-Months
Asset Growth
-17.32%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
DSGN Stock 12 Month Forecast
Average Price Target
$5.00
▼(-6.19% Downside)
Technical Analysis
Neurogene
―
Annexon Biosciences
―
Foghorn Therapeutics
―
4D Molecular Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
19.58% Insiders
6.71% Mutual Funds
0.16% Other Institutional Investors
67.80% Public Companies and
Individual Investors